Oveporexton

Oveporexton
Clinical data
Trade namesOrzeyful
Other namesTAK-861; TAK861
AHFS/Drugs.com
License data
Routes of
administration
Oral
Drug classOrexin OX2 receptor agonist
Legal status
Legal status
Pharmacokinetic data
Protein binding>96%
MetabolismCYP3A4
Onset of action1–4 hours (TmaxTooltip time to peak levels)
Elimination half-life16–24 hours
ExcretionFeces: 80.5%
Urine: 11.0%
Identifiers
  • N-[(2S,3R)-2-[[3-(3,5-difluorophenyl)-2-fluorophenyl]methyl]-4,4-difluoro-1-(2-hydroxy-2-methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC23H25F5N2O4S
Molar mass520.52 g·mol−1
3D model (JSmol)
  • CCS(=O)(=O)N[C@@H]1[C@@H](N(CC1(F)F)C(=O)C(C)(C)O)CC2=C(C(=CC=C2)C3=CC(=CC(=C3)F)F)F
  • InChI=1S/C23H25F5N2O4S/c1-4-35(33,34)29-20-18(30(12-23(20,27)28)21(31)22(2,3)32)10-13-6-5-7-17(19(13)26)14-8-15(24)11-16(25)9-14/h5-9,11,18,20,29,32H,4,10,12H2,1-3H3/t18-,20+/m0/s1
  • Key:KVMGAIOTUIGROS-AZUAARDMSA-N

Oveporexton, sold under the brand name Orzeyful, is a medication used for the treatment of narcolepsy type 1. It is taken by mouth.

The most common side effects include insomnia, increased urinary frequency, urgency to urinate, and increased saliva production. Oveporexton is an orexin OX2 receptor agonist.

Oveporexton was approved for medical use in China in July 2026, and in the United States in August 2026. It is recommended for scheduling under the Controlled Substances Act and will be lawful to market in the US following the scheduling decision issued by the Drug Enforcement Administration.